Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Imgatuzumab |
Synonyms | |
Therapy Description |
Imgatuzumab (RG7160) is a humanized antibody directed against EGFR, which prevents ligand binding and dimerization, resulting in decreased EGFR signaling and increased immune response toward EGFR-expressing tumor cells (PMID: 23209031, PMID: 28950289). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Imgatuzumab | RG7160|GA201|RG-7160|GA-201|RO 5083945|RO5083945 | EGFR Antibody 60 | Imgatuzumab (RG7160) is a humanized antibody directed against EGFR, which prevents ligand binding and dimerization, resulting in decreased EGFR signaling and increased immune response toward EGFR-expressing tumor cells (PMID: 23209031, PMID: 28950289). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04985825 | Phase II | Imgatuzumab | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE) | Withdrawn | 0 |